← Back to Search

Trigger Point Injections for Neck Pain

Phase 4
Recruiting
Research Sponsored by George Washington University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 hours after intervention
Awards & highlights

Study Summary

This trial is testing whether trigger point injections can help relieve myofascial pain (muscle pain) for people who have had anterior neck surgery.

Who is the study for?
This trial is for patients scheduled for elective anterior neck surgery who often experience postoperative neck stiffness and pain. It's not suitable for those with emergency surgeries, allergies to local anesthetics, long-term opioid use (except tramadol and codeine), or complications during surgery leading to an unstable cervical spine.Check my eligibility
What is being tested?
The study tests if trigger point injections with bupivacaine or normal saline can reduce myofascial pain after neck surgery better than standard care alone. The goal is to see if this treatment decreases the need for narcotic pain medication post-surgery.See study design
What are the potential side effects?
Possible side effects from the injections may include temporary discomfort at the injection site, bruising, infection risk, and allergic reactions to the numbing medications used.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 hours after intervention
This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 hours after intervention for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Opioid consumption in the first 12 hour period after intervention (trigger point injection/sham)
Opioid consumption in the first 24 hour period after intervention (trigger point injection/sham)
Opioid consumption in the first 6 hour period after intervention (trigger point injection/sham)
Secondary outcome measures
Pain score at 12 hours after intervention (trigger point injection/sham)
Pain score at 24 hours after intervention (trigger point injection/sham)
Pain
+1 more

Trial Design

3Treatment groups
Experimental Treatment
Active Control
Placebo Group
Group I: Trigger point injection with bupivacaineExperimental Treatment1 Intervention
Trigger point injections in the rhomboid and trapezius regions with up to 20cc of 0.25% bupivacaine hydrochloride + intra- and postoperative standardized analgesia regimen
Group II: Trigger point injection with normal salineActive Control1 Intervention
Trigger point injections in the rhomboid and trapezius regions with up to 20cc of 0.9% Normal Saline + intra- and postoperative standardized analgesia regimen
Group III: Lidocaine skin whealPlacebo Group1 Intervention
They will receive an injection of lidocaine in the skin over the area of the trigger points. While this causes a small area of numbness, it is not a trigger point injection.

Find a Location

Who is running the clinical trial?

George Washington UniversityLead Sponsor
243 Previous Clinical Trials
453,187 Total Patients Enrolled

Media Library

Trigger point injection with bupivacaine Clinical Trial Eligibility Overview. Trial Name: NCT04640896 — Phase 4
Myofascial Pain Research Study Groups: Lidocaine skin wheal, Trigger point injection with normal saline, Trigger point injection with bupivacaine
Myofascial Pain Clinical Trial 2023: Trigger point injection with bupivacaine Highlights & Side Effects. Trial Name: NCT04640896 — Phase 4
Trigger point injection with bupivacaine 2023 Treatment Timeline for Medical Study. Trial Name: NCT04640896 — Phase 4
~13 spots leftby Jun 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top